Miragen Therapeutics, Inc. (MGEN) News
Filter MGEN News Items
MGEN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest MGEN News From Around the Web
Below are the latest news stories about Miragen Therapeutics Inc that investors may wish to consider to help them evaluate MGEN as an investment opportunity.
miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership TeamJonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical OfficerViridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye diseaseCompany recently licensed exclusive rights from Xencor, Inc. to develop and commercialize therapeutic antibodies targeting IGF-1R incorporating Xtend™ Fc half-life extension technology BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“Viridian”). Beginning tomorrow, Viridian will trade on NASDAQ under the ticker symbol "VRDN" and its common stock will trade under a new CUSIP number, 92790C104. The Company also announced to... |
Oppenheimer: These 3 Stocks Could Spike Over 80%Wall Street’s best firms don’t just look at the stocks, they look at the big picture, too. And Oppenheimer’s chief investment strategist, John Stoltzfus, is particularly adept at showing us the macro view. In his first note of the new year, Stoltzfus notes a series of factors that are going to impact the markets. The big news, of course, the 800-pound gorilla that cannot be ignored, is the ongoing COVID epidemic. The disease is coming back strong now that we’re well into winter – which was somewhat expected, as it’s typical behavior for flu-like respiratory viruses. |
61 Biggest Movers From Yesterday - Stocks News FeedGainers Riot Blockchain, Inc. (NASDAQ: RIOT) shares jumped 48.4% to close at $6.09 on Tuesday amid strength in Bitcoin prices. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) shares jumped 40.3% to close at $1.81 on Tuesday as the company disclosed that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints. Miragen Therapeutics, Inc. (NASDAQ:… Read More »61 Biggest Movers From Yesterday |
MiRagen reports loss, effects reverse stock splitMiRagen Therapeutics Inc. (Nasdaq: MGEN), a Boulder-based biotechnology company developing new treatments for patients with diseases that are underserved by current therapies, reported a net loss o… |
miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates* Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED) * Private placement financing proceeds of approximately $91 million positions miRagen to potentially advance multiple compounds through Phase 2 proof of concept studies in TED and expand its orphan disease pipeline * After completion of the acquisition of Viridian Therapeutics and the private placement financing, miRagen has cash on hand of approximately $144 million and estimated cash runway through 2023 * Announces 1-for-15 reverse stock split to be effective as of November 12, 2020 and trading of the common stock will begin on a split-adjusted basis when markets open on November 13, 2020BOULDER, Colo... |
Arena (ARNA) Q3 Earnings Top, Stock Down on Eczema Study DataArena Pharmaceuticals (ARNA) beats bottom-line estimates for third-quarter 2020. Mid-stage atopic dermatitis study on etrasimod fails to meet primary endpoint but phase III study may start soon. |
Value-Added Acquisition Clears the Runway for Miragen TherapeuticsIt was thrilling to watch MGEN stock spike, and the bull move might not be over as Miragen's new acquisition puts high-need medicine in focus. |
Iovance (IOVA) Q3 Earnings Beat Estimates, Pipeline in FocusIovance's (IOVA) third-quarter earnings beat estimates. The company is progressing well with development of its lead pipeline candidate. |
Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat EstimatesSarepta (SRPT) Q3 revenues increase year over year. |
Clovis (CLVS) Q3 Earnings Top, Sales Show Coronavirus ImpactClovis (CLVS) reports mixed third-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares plunge. |